Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
What has led to the rising trend for Cell & Gene Therapy (CGT) developers to choose retroviral vectors over other potential vectors, and what are the many drivers behind this selection process?
IPT talks to Dr Fiona McLaughlin and Neil Bell of Avacta Therapeutics about the need for cohesion when researching and developing a new drug between life science companies, academia, and medical practitioners
The in vitro-in silico ‘alternative’ bioequivalence pathway for generic inhaled drug products, and how to factor in patient variability to successfully replace your comparative clinical end-point study
From tools and assays, to the need for improved collaboration, the potential answers to this question are numerous. IPT asked representatives from DeciBio, Cybin, and GORE PharmBIO for their opinions
Michael Avraam at ChargePoint Technology walks IPT through the challenges and obstacles that companies face when looking to build safety, quality, and efficiency into their potent active pharmaceutical ingredient (API) processes
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?